General Information of the Drug (ID: M6APDG02766)
Name
3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
Synonyms
3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 9; AC1O70HH; SCHEMBL4507080; CHEMBL206070
    Click to Show/Hide
Status
Investigative
Structure
Formula
C16H15N
InChI
1S/C16H15N/c1-12-9-15(14-6-4-8-17-11-14)10-13-5-2-3-7-16(12)13/h2-8,10-12H,9H2,1H3
InChIKey
HIOBIABFPPEMPT-UHFFFAOYSA-N
PubChem CID
6540053
TTD Drug ID
D0X1QS
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aromatase (CYP19A1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Aromatase (CYP19A1) is a therapeutic target for 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine through regulating the expression of Aromatase (CYP19A1). [1], [2]
References
Ref 1 Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018 Sep;233(9):7055-7066. doi: 10.1002/jcp.26507. Epub 2018 Mar 25.
Ref 2 Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem. 2006 Apr 6;49(7):2222-31. doi: 10.1021/jm060055x.